Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Secondary AML, Myelodysplastic Syndrome (MDS), Secondary MDS, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Paroxysmal Nocturnal Hemoglobinuria (PNH), Lymphoma, Non-Hodgkin, Hodgkin Disease
Interventions: Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies; Procedure · Device · Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Wound Complication
Interventions: Prevena, Aquacel; Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Feasibility Studies
Interventions: Physical activity intervention using traditional strength training protocols, Physical activity intervention using high-resistance circuit training.; Other
Lead sponsor: University of Utah; Other
Eligibility: 14 Years to 19 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Hypoxemia During Surgery
Interventions: HFNO-Treatment; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Melanoma (Skin)
Interventions: QS21, IFA (incomplete Freund's adjuvant), p946, p946/tet-p, Tet-p; Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions: TG4050; Drug
Lead sponsor: Transgene; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Body Image, Eating Behavior, Binge Eating, Nutrition, Healthy, Disordered Eating
Interventions: BABE (Body Appreciation and Better Eating); Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Multiple Myeloma, Smoldering Multiple Myeloma
Interventions: Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2040
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sarcoma
Interventions: filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, mesna, conventional surgery, brachytherapy, intraoperative radiation therapy, radioisotope therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2013
U.S. locations: 220
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 169 more

Conditions: Kidney Neoplasms
Interventions: Sunitinib malate, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 12
States / cities: Los Angeles, California • Atlanta, Georgia • Marrero, Louisiana + 7 more

Conditions: Hypercholesterolemia, Cardiovascular Diseases
Interventions: lerodalcibep, evolocumab, alirocumab; Biological
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration; Drug · Procedure · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 338
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more

Conditions: Coronary Artery Disease
Interventions: CT angiography, Invasive coronary angiography; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 45 Years to 85 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adenomatous Polyp
Interventions: Aspirin, Eflornithine, Laboratory Biomarker Analysis, Placebo, Telephone-Based Intervention; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 40 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 3
States / cities: Chicago, Illinois • Rochester, Minnesota

Conditions: Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography, Leukapheresis, Lumbar Puncture, Magnetic Resonance Imaging, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Multigated Acquisition Scan, Positron Emission Tomography, Transplant Conditioning, X-Ray Imaging; Procedure · Biological · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: HIGH GRADE GLIOMA
Interventions: TH-302 preoperative, Placebo, TH-302 (escalating) with bevacizumab 10mg/kg; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostate Cancer
Interventions: Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 612 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2022
U.S. locations: 245
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more

Conditions: Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography, Etoposide, Magnetic Resonance Imaging, Mosunetuzumab, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine; Procedure · Drug · Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Metastatic Melanoma
Interventions: Proleukin and Dacarbazine; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Lung Cancer
Interventions: Not listed
Lead sponsor: bioAffinity Technologies Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Summit, New Jersey • Albuquerque, New Mexico • San Antonio, Texas

Conditions: Atherosclerosis, Cardiovascular Disease
Interventions: any statin, niacin, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2, Hypoxemic Respiratory Failure, Pneumonia, Viral, COVID
Interventions: Helmet Continuous Positive Airway Pressure (CPAP), High Flow Nasal Oxygen (HFNO); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension, Blood Pressure, Cardiovascular Diseases, Cardiovascular Risk Factor, Autonomic Nervous System Imbalance
Interventions: HIRREM, Continued Current Care; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Major Depressive Disorder (MDD), Suicidal Ideation
Interventions: TMS; Device
Lead sponsor: University of California, Davis; Other
Eligibility: 15 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Search by objective public record fields.

Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies

Closed Incision Negative Pressure Therapy vs Standard of Care

Feasibility Study of Resistance Training Intervention in Untrained Adolescents

High-flow Nasal Oxygen Therapy for Advanced Endoscopy in High-risk Patients.

Vaccine Therapy in Treating Patients With Metastatic Melanoma

A Trial Evaluating TG4050 in Ovarian Carcinoma.

BABE(Body Appreciation and Better Eating), Add Some Self-compassion

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Ultra-high-resolution CT vs. Conventional Angiography for Detecting Coronary Heart Disease

Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients

Collection of Sputum and Labeling for Lung Cancer

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia

HIRREM for Stage 1 Primary Hypertension

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk